Doss Sheila, Schiller Brigitte
Satellite Healthcare, Inc., San Jose, CA, USA.
Nephrol Nurs J. 2010 Nov-Dec;37(6):617-26.
Erythropoiesis stimulating agents (ESAs) have revolutionized the management of anemia of chronic kidney disease (CKD). Peginesatide is an investigational pegylated, peptide-based, once-monthly ESA for increasing and maintaining hemoglobin (Hb). In phase 2 studies, peginesatide increases and maintains target Hb levels in patients with CKD, both those on hemodialysis and those not on hemodialysis; phase 3 trials have recently been completed. This article discusses unmet needs in the management of anemia of CKD, presents peginesatide attributes, reviews the results of select peginesatide clinical studies, and discusses the potential value of peginesatide as an alternative anemia management option.
促红细胞生成素（ESAs）彻底改变了慢性肾脏病（CKD）贫血的治疗方式。聚乙二醇化促红细胞生成素是一种处于研究阶段的聚乙二醇化、基于肽的促红细胞生成素，每月给药一次，用于提高并维持血红蛋白（Hb）水平。在2期研究中，聚乙二醇化促红细胞生成素可提高并维持CKD患者（包括接受血液透析和未接受血液透析的患者）的目标Hb水平；3期试验最近已经完成。本文讨论了CKD贫血治疗中尚未满足的需求，介绍了聚乙二醇化促红细胞生成素的特性，回顾了聚乙二醇化促红细胞生成素部分临床研究的结果，并讨论了聚乙二醇化促红细胞生成素作为一种替代性贫血治疗选择的潜在价值。
